A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

NCT04582409 | Terminated Phase 2 Results FDA Drug

• 2 other identifiers: CHSY244X22012020-004327-17
• Study Type: interventional
• Target: 13
• Locations: 2 countries
• Sites: 4

Brief Summary

This was a randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of HSY244 in participants with atrial fibrillation (AF), with and without heart failure (HF).

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation; arrhythmia; pharmacological cardioversion

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Conversion to Sinus Rhythm for at Least 1 Minute Within 90 Minutes From the Start of Study Drug Administration.

  Conversion to sinus rhythm was monitored using a Holter monitoring device through 90 minutes after the start of study drug administration. If a participant had been monitored for at least 45 minutes and did not convert to sinus rhythm for at least one minute, the primary endpoint was defined as 'no'. If a participant converted to sinus rhythm for at least one minute at any time during the post-treatment 90 minutes observation period, regardless of the length of time monitored, the primary endpoint was to be defined as 'yes'.

  90 minutes from the start of study drug administration

Secondary Outcomes (3)

• Maximum Observed Plasma Concentration (Cmax)

  Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5

• Time to Reach the Maximum Concentration After Drug Administration (Tmax)

  Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5

• Area Under the Plasma Concentration-time Curve (AUClast)

  Day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and Day 5

Study Arms (2)

HSY244

EXPERIMENTAL

HSY244 150 mg concentrate solution for injection via intravenous infusion

Drug: HSY244

Placebo

PLACEBO COMPARATOR

Placebo concentrate solution for injection via intravenous infusion

Other: Placebo

Interventions

HSY244 DRUG

HSY244 concentrate solution for injection via intravenous infusion

HSY244

Placebo OTHER

Placebo concentrate solution for injection via intravenous infusion

Placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At screening, written informed consent were required to be obtained before any assessment was performed and only participants able to provide written informed consent themselves were included in this study.
• Hemodynamically stable men and women (either of non-child-bearing potential or child bearing potential with highly effective contraception) between 18 and 80 years of age (inclusive) at screening with a clinical indication for direct current cardioversion of AF.
• At screening, current episode of AF had been ongoing for ≥6 hours and ≤60 days
• Successful initiation and achievement of therapeutic levels of national guideline and institution-specific anticoagulation therapy as appropriate for the duration of the AF episode and risk for the participant.
• Completion of national guideline and institution-specific imaging evaluation for left atrial thrombi as appropriate for the duration of AF episode and risk for the participant.
• At screening, participants were required to weigh at least 60 kg to participate in the study and were required to have a body mass index (BMI) within the range of 18 - 45 kg/m\^2. BMI = Body weight (kg) / \[Height (m)\]\^2
• At screening, vital signs (systolic blood pressure and pulse rate) were assessed in the sitting position. Sitting vital signs were required to be within the following ranges (exclusive):
• systolic blood pressure between 100-160 mmHg and diastolic blood pressure 60-100 mmHg
• pulse rate (ventricular rate) between 60-120 bpm.

You may not qualify if:

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
• Sexually active males unwilling to use a condom during intercourse while taking investigational drug and for 96 hours after study drug administration. A condom was required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner. In addition, male participants could not donate sperm for the time period specified above.
• Use of any anti-arrhythmic class I or III drug (including Ranolazine \[Ranexa\]) within 5 half lives before randomization; including use of amiodarone within 3 months before randomization.
• At screening, history of current diagnosis of ECG abnormalities or cardiac rhythm disorders as determined by the Investigator's interpretation of the ECG findings indicating a significant risk for participating in the study, such as:
• History of Torsades de Pointes (TdP), any other polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, long QT syndrome, or Brugada syndrome.
• Wolfe-Parkinson-White (WPW) syndrome
• In the absence of a complete bundle branch block a resting QTcF \>460 msec for men and \>470 msec for women (mean of ≥ 5 consecutive QT intervals)
• In the presence of a complete bundle branch block, a prolonged QTcF or JTc that, in the opinion of the investigator, may pose a risk to patient safety
• Third-degree (complete) heart block, or second-degree Mobitz type II heart block
• Attempted or unsuccessful cardioversion within 2 weeks prior to randomization.
• Presence of known severe mitral regurgitation and/or known severely dilated left atrium.
• Pre-existing or tachycardia-induced moderate to severe cardiac dysfunction (New York Heart Association Class III and IV).
• History within the preceding 3 months prior to randomization of: myocardial infarction, unstable angina, cardiac surgery, or a percutaneous coronary intervention.
• History of a confirmed stroke or transient ischemic attack (TIA).
• History or current diagnosis of any seizure disorder, epilepsy, significant head trauma, or other disorders increasing the risk for seizures.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (4)

Novartis Investigative Site

Boston, Massachusetts, 02215, United States

Location

Novartis Investigative Site

Lansing, Michigan, 48912, United States

Location

Novartis Investigative Site

Bad Oeynhausen, 32545, Germany

Location

Novartis Investigative Site

Frankfurt, 60590, Germany

Location

Related Links

• Results for CHSY244X2201 that is getting linked from the Novartis Clinical Trials Website
• Patient Lay Trial Summary

MeSH Terms

Conditions

Atrial Fibrillation; Arrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Study Director
• Organization: Novartis Pharmaceuticals

Novartis.email@Novartis.com

+ 1 862 778 8300

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 7, 2020
• First Posted: October 9, 2020
• Study Start: November 30, 2020
• Primary Completion: July 11, 2022
• Study Completion: July 11, 2022
• Last Updated: June 20, 2024
• Results First Posted: July 25, 2023

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will share

Locations

US (2); DE (2)